In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.
Random assignment of 1018 patients showed durable DFS improvement with durvalumab+BCG induction/maintenance vs BCG (12-to-48 month DFS: 92%–80% vs 87%–75%), while ...
Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...
ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality ...
Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI ...
New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...
PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics. In the final episode of this commentary, ...
De-escalated options for marker-negative stage IIA/B seminoma include nerve-sparing RPLND for ≤3 cm nodes or focused radiotherapy plus 1 cycle carboplatin in selected patients. Centralization is ...
Multisite validation in 330 GG1 patients found 9.4% upgraded to GG3+ and 37% to GG2+ on systematic plus MRI-targeted biopsy, establishing a clinically relevant upgrading prevalence. Superior ...
Breakthrough Device Designation was granted to a urine-based VOC spectroscopy/ML MCED test targeting prostate, bladder, and kidney cancers, potentially broadening non-blood screening modalities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results